Clinical Trials Logo
  1. Home
  2. ANCA-associated Vasculitis
  3. NCT04664465

PRediction Of DIverse Glucocorticoids toxIcity OUtcomeS — PRODIGIOUS  

Giant Cell Arteritis Clinical Trial

Official title:
PRediction Of DIverse Glucocorticoids toxIcity OUtcomeS

Clinical Trial Summary

To date, there is no available tool that allows, at individual level, determination of the probability to develop clinically relevant complications of prolonged glucocorticoid therapy. In patients with inflammatory rheumatic disorders requiring prolonged glucocorticoid therapy, such tool could be useful to adapt first-line treatment decisions (in daily practice and in future clinical trials). The main objective of the study is to identify routine clinical, biological and DXA baseline characteristics predictive of the occurrence of clinically relevant complications of glucocorticoid therapy at 1 year, in order to propose a predictive score.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04664465
Study type Observational
Source University Hospital, Brest
Contact Dewi GUELLEC
Phone 02-98-34-72-64
Email dewi.guellec@chu-brest.fr
Status Recruiting
Phase
Start date March 18, 2021
Completion date March 18, 2024
View Details
See also
  Status Clinical Trial Phase
Completed NCT03812302 - Use of Gallium-68 HA-DOTATATE PET/CT in Giant Cell Arteritis (GCA) Phase 2
Recruiting NCT02257866 - Studies of the Natural History, Pathogenesis, and Outcome of Idiopathic Systemic Vasculitis
Recruiting NCT04888221 - Efficacy of Tocilizumab in Association to Steroids in Giant Cell Arteritis With Cerebro-vascular Involvement Phase 3
Recruiting NCT05380453 - Efficacy and Safety of Secukinumab in Patients With New Onset of Giant Cell Arteritis Who Are in Clinical Remission Phase 3
Recruiting NCT02333708 - Study of Circulating Microparticles in Giant Cell Arteritis
Completed NCT01450137 - Tocilizumab for Patients With Giant Cell Arteritis Phase 2
Completed NCT03827018 - KPL-301 for Subjects With Giant Cell Arteritis Phase 2
Active, not recruiting NCT04519580 - Improved Diagnostics and Monitoring of Polymyalgia Rheumatica
Recruiting NCT04239196 - Efficacy of Tocilizumab for the Treatment of Acute AION Related to GCA Phase 2
Recruiting NCT06460142 - Assessing Biomarker in Giant Cell Arteritis and Polymyalgia Rheumatic
Completed NCT03202368 - An Extension Study to Evaluate Long-Term Safety of Subcutaneous (SC) Tocilizumab in Participants With Giant Cell Arteritis (GCA) Phase 3
Not yet recruiting NCT02523625 - Giant Cell Arteritis: Improving Use of Ultrasound Evaluation N/A
Completed NCT03285945 - FDG Uptake in Large-Vessel Giant Cell Arteritis After Short-term, High-Dose Steroid Treatment N/A
Completed NCT02190916 - Vasculitis Illness Perception (VIP) Study N/A
Recruiting NCT01241305 - One-Time DNA Study for Vasculitis
Terminated NCT02531633 - Efficacy and Safety Study of Sirukumab in Patients With Giant Cell Arteritis Phase 3
Completed NCT03409913 - Diagnostic Accuracy of FDG PET/CT of Cranial Arteries in GCA N/A
Completed NCT03765424 - Evaluation of Ultrasound and PET/CT in the Diagnosis and Monitoring of Giant Cell Arteritis
Completed NCT01910038 - Evaluation of Tocilizumab as an add-on Therapy to Corticoids in Giant Cell Arteritis: Proof of Concept Study. Phase 2
Not yet recruiting NCT04012905 - Giant Cell Arteritis: Comparison Between Two Standardized Corticosteroids Tapering Phase 3